Cargando…

Ablation of cardiac myosin–binding protein-C accelerates contractile kinetics in engineered cardiac tissue

Hypertrophic cardiomyopathy (HCM) caused by mutations in cardiac myosin–binding protein-C (cMyBP-C) is a heterogenous disease in which the phenotypic presentation is influenced by genetic, environmental, and developmental factors. Though mouse models have been used extensively to study the contracti...

Descripción completa

Detalles Bibliográficos
Autores principales: de Lange, Willem J., Grimes, Adrian C., Hegge, Laura F., Ralphe, J. Carter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536521/
https://www.ncbi.nlm.nih.gov/pubmed/23277475
http://dx.doi.org/10.1085/jgp.201210837
_version_ 1782254753243201536
author de Lange, Willem J.
Grimes, Adrian C.
Hegge, Laura F.
Ralphe, J. Carter
author_facet de Lange, Willem J.
Grimes, Adrian C.
Hegge, Laura F.
Ralphe, J. Carter
author_sort de Lange, Willem J.
collection PubMed
description Hypertrophic cardiomyopathy (HCM) caused by mutations in cardiac myosin–binding protein-C (cMyBP-C) is a heterogenous disease in which the phenotypic presentation is influenced by genetic, environmental, and developmental factors. Though mouse models have been used extensively to study the contractile effects of cMyBP-C ablation, early postnatal hypertrophic and dilatory remodeling may overshadow primary contractile defects. The use of a murine engineered cardiac tissue (mECT) model of cMyBP-C ablation in the present study permits delineation of the primary contractile kinetic abnormalities in an intact tissue model under mechanical loading conditions in the absence of confounding remodeling events. We generated mechanically integrated mECT using isolated postnatal day 1 mouse cardiac cells from both wild-type (WT) and cMyBP-C–null hearts. After culturing for 1 wk to establish coordinated spontaneous contraction, we measured twitch force and Ca(2+) transients at 37°C during pacing at 6 and 9 Hz, with and without dobutamine. Compared with WT, the cMyBP-C–null mECT demonstrated faster late contraction kinetics and significantly faster early relaxation kinetics with no difference in Ca(2+) transient kinetics. Strikingly, the ability of cMyBP-C–null mECT to increase contractile kinetics in response to adrenergic stimulation and increased pacing frequency were severely impaired. We conclude that cMyBP-C ablation results in constitutively accelerated contractile kinetics with preserved peak force with minimal contractile kinetic reserve. These functional abnormalities precede the development of the hypertrophic phenotype and do not result from alterations in Ca(2+) transient kinetics, suggesting that alterations in contractile velocity may serve as the primary functional trigger for the development of hypertrophy in this model of HCM. Our findings strongly support a mechanism in which cMyBP-C functions as a physiological brake on contraction by positioning myosin heads away from the thin filament, a constraint which is removed upon adrenergic stimulation or cMyBP-C ablation.
format Online
Article
Text
id pubmed-3536521
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-35365212013-07-01 Ablation of cardiac myosin–binding protein-C accelerates contractile kinetics in engineered cardiac tissue de Lange, Willem J. Grimes, Adrian C. Hegge, Laura F. Ralphe, J. Carter J Gen Physiol Article Hypertrophic cardiomyopathy (HCM) caused by mutations in cardiac myosin–binding protein-C (cMyBP-C) is a heterogenous disease in which the phenotypic presentation is influenced by genetic, environmental, and developmental factors. Though mouse models have been used extensively to study the contractile effects of cMyBP-C ablation, early postnatal hypertrophic and dilatory remodeling may overshadow primary contractile defects. The use of a murine engineered cardiac tissue (mECT) model of cMyBP-C ablation in the present study permits delineation of the primary contractile kinetic abnormalities in an intact tissue model under mechanical loading conditions in the absence of confounding remodeling events. We generated mechanically integrated mECT using isolated postnatal day 1 mouse cardiac cells from both wild-type (WT) and cMyBP-C–null hearts. After culturing for 1 wk to establish coordinated spontaneous contraction, we measured twitch force and Ca(2+) transients at 37°C during pacing at 6 and 9 Hz, with and without dobutamine. Compared with WT, the cMyBP-C–null mECT demonstrated faster late contraction kinetics and significantly faster early relaxation kinetics with no difference in Ca(2+) transient kinetics. Strikingly, the ability of cMyBP-C–null mECT to increase contractile kinetics in response to adrenergic stimulation and increased pacing frequency were severely impaired. We conclude that cMyBP-C ablation results in constitutively accelerated contractile kinetics with preserved peak force with minimal contractile kinetic reserve. These functional abnormalities precede the development of the hypertrophic phenotype and do not result from alterations in Ca(2+) transient kinetics, suggesting that alterations in contractile velocity may serve as the primary functional trigger for the development of hypertrophy in this model of HCM. Our findings strongly support a mechanism in which cMyBP-C functions as a physiological brake on contraction by positioning myosin heads away from the thin filament, a constraint which is removed upon adrenergic stimulation or cMyBP-C ablation. The Rockefeller University Press 2013-01 /pmc/articles/PMC3536521/ /pubmed/23277475 http://dx.doi.org/10.1085/jgp.201210837 Text en © 2013 de Lange et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Article
de Lange, Willem J.
Grimes, Adrian C.
Hegge, Laura F.
Ralphe, J. Carter
Ablation of cardiac myosin–binding protein-C accelerates contractile kinetics in engineered cardiac tissue
title Ablation of cardiac myosin–binding protein-C accelerates contractile kinetics in engineered cardiac tissue
title_full Ablation of cardiac myosin–binding protein-C accelerates contractile kinetics in engineered cardiac tissue
title_fullStr Ablation of cardiac myosin–binding protein-C accelerates contractile kinetics in engineered cardiac tissue
title_full_unstemmed Ablation of cardiac myosin–binding protein-C accelerates contractile kinetics in engineered cardiac tissue
title_short Ablation of cardiac myosin–binding protein-C accelerates contractile kinetics in engineered cardiac tissue
title_sort ablation of cardiac myosin–binding protein-c accelerates contractile kinetics in engineered cardiac tissue
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536521/
https://www.ncbi.nlm.nih.gov/pubmed/23277475
http://dx.doi.org/10.1085/jgp.201210837
work_keys_str_mv AT delangewillemj ablationofcardiacmyosinbindingproteincacceleratescontractilekineticsinengineeredcardiactissue
AT grimesadrianc ablationofcardiacmyosinbindingproteincacceleratescontractilekineticsinengineeredcardiactissue
AT heggelauraf ablationofcardiacmyosinbindingproteincacceleratescontractilekineticsinengineeredcardiactissue
AT ralphejcarter ablationofcardiacmyosinbindingproteincacceleratescontractilekineticsinengineeredcardiactissue